Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechnology for Unspecified B-Cell Lymphomas: Likelihood of Approval
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas....
Data Insights
CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic...